Table of Contents
Table of Contents 3
List of Tables 10
List of Figures 12
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 14
Gilead Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 15
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 16
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 17
Gilead Sciences Inc, Medical Devices Deals, 2011 to YTD 2017 19
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 20
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 28
Asset Purchase 28
Gilead Sciences Acquires Farnesoid X Receptor Program from Phenex Pharma 28
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 30
Venture Financing 31
Cell Design Labs Raises USD34.4 Million in Venture Financing 31
Kite Pharma Raises US$20 Million In Series A Financing 32
Kite Pharma Raises US$0.2 Million In Venture Financing 33
Kite Pharma Raises US$15 Million In Initial Round Of Financing 34
Partnerships 35
Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 35
Janssen Amends Licensing Agreement with Gilead for STR 36
Spring Bank Pharma Enters into Agreement with Gilead Sciences 37
Kite Pharma Forms Joint Venture with Fosun Pharma 38
Kite Pharma Enters into Agreement with Vitruvian Networks 39
Kite Pharma Enters into R&D Agreement with National Cancer Institute 40
Kite Pharma Enters into Agreement with Genentech 41
Gilead Sciences Enters into Co-Development Agreement with Galapagos 42
Kite Pharma Enters into Research Agreement with Leiden University Medical Center 43
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 44
Kite Pharma Enters into Research Agreement with GE Global Research 45
Spring Bank Pharma Enters into Agreement with Gilead Sciences 46
X-Rx Enters into Agreement with Gilead Sciences 47
Gilead Sciences Partners with WuXi PharmaTech 48
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 49
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 50
Adimab Enters into Research Agreement with Kite Pharma 51
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 52
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 53
Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 54
Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 55
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 56
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 58
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 59
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 60
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 62
Adimab Enters Into Co-Development Agreement With Gilead Sciences 63
CanAm Bioresearch Enters Into An Agreement With EpiTherapeutics 64
Zhejiang Conba Plans To Form Joint Venture With Kite Pharma 65
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine 66
Licensing Agreements 67
Gilead Sciences Enters into Licensing Agreement with Medicines Patent Pool 67
Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 68
Genmab Enters into Licensing Agreement with Gilead Sciences 69
Kite Pharma Enters into Licensing Agreement with Cell Design Labs 70
Kite Pharma Exercises Option for Licensing Agreement with Adimab 71
Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 72
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 73
Amgen Enters into Licensing Agreement with Kite Pharma 75
Janssen Expands Licensing Agreement with Gilead 77
Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 78
Gilead Sciences Expands Licensing Agreement with Mylan Labs 79
Gilead Sciences Expands Licensing Agreement with Strides Shasun 80
Gilead Sciences Expands Licensing Agreement with Sun Pharma 82
Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 83
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 84
Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 85
Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 86
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 87
Medicines Patent Pool Enters into Licensing Agreement with Gilead Sciences 88
Fosun Pharma Kite Biotechnology Receives an Option to Product Candidates from Kite Pharma 89
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 90
Gilead Sciences Enters into Licensing Agreement with Polyphor 91
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 92
Kite Pharma Enters into Licensing Agreement with Regents of the University of California 93
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 94
Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 95
Natco Pharma Enters into Licensing Agreement with Gilead Sciences 96
Gilead Sciences Expands Licensing Agreement with Mylan Labs 97
Biocon Enters into Licensing Agreement with Gilead Sciences 98
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 99
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 100
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 102
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 103
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 104
Gilead Sciences Enters into Licensing Agreement with Hetero Labs 105
Gilead Sciences Enters into Licensing Agreement with Cipla 106
Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 107
Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 108
Gilead Sciences Plans To License Hepatitis C Drug, Sovaldi 109
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 110
Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 111
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 112
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 114
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 115
Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 116
Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 117
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat 118
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 119
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 120
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune 121
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 122
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 123
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 125
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad 126
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad 127
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 128
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 129
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread 130
VetDC Enters Into Licensing Agreement With Gilead Sciences For GS 9219 131
Equity Offering 132
Kite Pharma Raises USD409.7 Million in Public Offering of Shares 132
Galapagos Raises USD425 Million in Private Placement of Shares 134
Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 135
Kite Pharma Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 137
Kite Pharma Announces Full Exercise of Underwriters Option in IPO to Raise up to USD147 Million 139
Debt Offering 141
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 141
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 143
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 145
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 147
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 149
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 151
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 153
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 155
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 157
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 159
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 161
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 163
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 165
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 167
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 169
Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 171
Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 173
Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 175
Gilead Sciences Completes Public Offering Of Notes Due 2044 For US$1.75 Billion 177
Gilead Sciences Completes Public Offering Of Notes Due 2024 For US$1.75 Billion 179
Gilead Sciences Completes Public Offering Of Notes Due 2019 For US$500 Million 181
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1.25 Billion 183
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$1 Billion 184
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$700 Million 185
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 186
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1,000 Million 187
Asset Transactions 188
Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences 188
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 189
Acquisition 190
Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 190
United Therapeutics May Sell Itself 192
Gilead Sciences May Acquire Incyte 193
Novartis May Acquire Intercept Pharma 194
Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 195
Gilead Sciences Acquires EpiTherapeutics for USD65 Million 196
Kite Pharma Acquires T-Cell Factory 197
Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 198
Gilead Sciences Completes Acquisition Of Pharmasset For US$11.2 Billion 200
Gilead Sciences Acquires Calistoga Pharma 202
Gilead Sciences Acquires Arresto Biosciences 204
Gilead Sciences Inc – Key Competitors 206
Gilead Sciences Inc – Key Employees 207
Gilead Sciences Inc – Locations And Subsidiaries 208
Head Office 208
Other Locations & Subsidiaries 208
Joint Venture 212
Recent Developments 213
Financial Announcements 213
Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 213
Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 215
May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 217
Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 219
Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results 221
Jul 25, 2016: Gilead Sciences Announces Second Quarter 2016 Financial Results 223
Apr 28, 2016: Gilead Sciences Announces First Quarter 2016 Financial Results 225
Feb 02, 2016: Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results 227
Corporate Communications 230
Sep 27, 2017: Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire 230
Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences’ Board of Directors 231
May 24, 2016: Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy 232
Jan 29, 2016: Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director 233
Jan 29, 2016: AHF: Gilead Billionaire CEO John Martin Steps Down 234
Legal and Regulatory 235
Dec 16, 2016: Merck’s subsidiary wins $2.5bn patent verdict against Gilead Sciences 235
Mar 25, 2016: AHF: Gilead Says it “Had No Duty to Develop” Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit 236
Mar 22, 2016: Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case 238
Government and Public Interest 239
Nov 03, 2017: Abraham Brass receives grant from Gilead for HIV research 239
Oct 16, 2017: Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research 240
Jan 10, 2017: Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research 241
Jan 09, 2017: Mercy Philadelphia Hospital Receives FOCUS Award from Gilead Sciences 243
Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science’s Massive Offshore Tax Dodging 244
Mar 10, 2016: $3.8M grant awarded to surgeon to test transplant drug 245
Feb 22, 2016: Gilead Launches New Grants Program to Support HIV Cure 246
Product News 247
Nov 09, 2016: New Therapeutic Vaccine Approach Holds Promise for HIV Remission 247
11/03/2016: Kite Pharma to Present KTE-C19 Data from Interim Analysis of the ZUMA-1 Pivotal Trial in Patients with Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL) at the 2016 American Society Hematology Annual Meeting 249
11/02/2016: Abzena Provides Update on GS-5745 251
11/01/2016: Nimbus Therapeutics Announces $200 Million Milestone Payment from Gilead Sciences for Allosteric ACC Inhibitor Program in Non-alcoholic Steatohepatitis 252
10/25/2017: Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy 253
10/19/2017: BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy 255
10/19/2016: Kite Pharma Provides Update on KTE-C19 and Launch Preparedness at Investor Day 256
10/18/2017: Kite’s Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy 257
10/18/2017: City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell Therapy for Adult Patients with Certain Types of Large B-cell Lymphoma 259
10/18/2017: UChicago Medicine first site in Illinois offering pioneering CAR T-cell therapy for cancer 260
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 262
10/13/2016: Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial Operations and Advance the Company’s CAR/TCR Therapy Portfolio in the Region 264
10/11/2016: Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry-Leading CAR/TCR Pipeline, Next Generation Research and Development, and KTE-C19 Launch Readiness 265
10/06/2016: Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) 266
09/25/2017: China Food and Drug Administration Approves Gilead’s Sovaldi (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection 267
09/23/2016: NICE says yes to another hepatitis C drug 268
08/10/2017: Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV 269
07/20/2017: Gilead Sciences International Receives CHMP Positive Opinion for Sovaldi 270
07/18/2016: Axium Healthcare Pharmacy Now Dispensing Epclusa, the First Oral Medication FDA-Approved to Treat All Hepatitis C Genotypes 271
07/14/2016: Gilead receives approval in Canada for EPCLUSA (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C 272
06/28/2016: FDA approves Epclusa for treatment of chronic Hepatitis C virus infection 273
06/20/2016: Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility 274
06/14/2017: Court Decides It Lacks Jurisdiction Before FDA Approval Occurs 275
06/06/2016: Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma 276
05/26/2017: Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel 277
05/17/2017: Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting 278
04/21/2017: Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017 280
04/16/2016: Scientists find a way to cure hepatitis C with 6 weeks of treatment 281
04/15/2016: Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs at the Annual Meeting of the American Association for Cancer Research (AACR) 282
04/07/2017: FDA approves hepatitis C drug Sovaldi (sofosbuvir) for pediatric patients 284
04/02/2017: Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting 285
03/30/2017: Kite to Present on Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting 287
03/29/2016: Children’s Hospital Los Angeles to Initiate Clinical Trial for Kids with Treatment-Resistant Leukemia 288
03/16/2016: Kite Pharma Deepens Cell Manufacturing and Operations Expertise with Appointment of Tim Moore 289
03/06/2017: John Theurer Cancer Center part of multi-center study with National Cancer Institute and Kite Pharma for CAR-T Cell Therapy Study Showing Very Impressive Results in Aggressive Lymphoma Refractory to Chemotherapy 290
03/03/2016: Novel small-molecule antiviral compound protects monkeys from deadly Ebola virus 291
02/28/2017: Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma 292
02/24/2016: Kite Pharma Augments Commercial Leadership Team 294
02/16/2016: U.S. FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease 296
01/05/2017: Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors 297
Product Approvals 298
Jul 31, 2017: Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel 298
Jul 13, 2017: European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV 299
Jun 12, 2017: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment 300
Mar 31, 2017: Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL) 301
Dec 04, 2016: Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma 302
Aug 15, 2016: JT files New Drug Application for second tenofovir alafenamide (TAF)-based anti-HIV drug in Japan 303
Jul 08, 2016: European Commission Grants Marketing Authorization for Gilead’s Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C 304
Jun 01, 2016: Kite Pharma Granted Access to Priority Medicines (PRIME) Regulatory Support for KTE-C19 in the Treatment of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL) 305
May 27, 2016: EMA recommends new combination therapy against chronic hepatitis C 306
May 02, 2016: Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications 307
Apr 25, 2016: European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV 308
Apr 05, 2016: Novel anti-HIV drug Descovy received US regulatory approval, JT’s partner Gilead Sciences announced 309
Apr 04, 2016: U.S. Food and Drug Administration Approves Descovy (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy 310
Feb 26, 2016: European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV 312
Feb 02, 2016: Nimbus Therapeutics Granted Fast Track Designation for Its Allosteric ACC Inhibitor, NDI-010976, for the Treatment of NASH 313
Jan 04, 2016: Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection 314
Clinical Trials 315
Oct 04, 2017: Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens 315
Aug 07, 2017: Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union 316
Aug 02, 2017: Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5) 317
Jul 24, 2017: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV 318
Jun 24, 2017: European Hematology Association: Clinical and Biologic Covariates of Outcomes in ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive non-Hodgkin Lymphoma (NHL) 319
Jun 05, 2017: HalioDx highlights use of Immunosign to define CAR T-cell therapy signature in tumor at ASCO 2017 320
Jun 05, 2017: Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 321
May 30, 2017: Gileads Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies 322
Apr 06, 2017: Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards 323
Feb 13, 2017: Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors 324
Feb 13, 2017: Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV 325
Jan 05, 2017: Immune cell therapy shows promising results for lymphoma patients 326
Dec 06, 2016: Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Society of Hematology 327
Dec 04, 2016: Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 328
Nov 21, 2016: Kite Pharma to Present Interim Results from the ZUMA-1 Pivotal Trial of KTE-C19 in a Late-Breaking Session at the 2016 American Society of Hematology Annual Meeting 329
Oct 07, 2016: Kite Pharma Presents 12-Month Follow-Up Data from ZUMA-1 Phase 1 at the European Society for Medical Oncology Annual Congress 330
Sep 26, 2016: Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) 331
Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis 332
Jul 07, 2016: Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1) 333
Jul 05, 2016: PREVAIL treatment trial for men with persistent Ebola viral RNA in semen opens in Liberia 334
Jun 08, 2016: Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress 335
Jun 06, 2016: Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma 337
May 31, 2016: Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting 338
May 24, 2016: Novel immunotherapy trial for lymphoma offers hope to patients at Sylvester 340
Apr 28, 2016: Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 341
Apr 19, 2016: Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting 342
Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016 344
Apr 16, 2016: Gilead Presents Phase 2 Results On Harvoni At The International Liver CongressTM 2016 345
Apr 16, 2016: Gilead Presents Phase 3 Data On Sofosbuvir/Velpatasvir At The International Liver CongressTM 2016 346
Mar 16, 2016: Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research 347
Feb 24, 2016: Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys 349
Feb 23, 2016: Phenex Announces Milestone Payment from Gilead as FXR drug candidate GS-9674 Enters Phase I Study 350
Appendix 351
Methodology 351
About GlobalData 351
Contact Us 351
Disclaimer 351
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 14
Gilead Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 15
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 16
Gilead Sciences Inc, Deals By Therapy Area, 2011 to YTD 2017 17
Gilead Sciences Inc, Medical Devices Deals, 2011 to YTD 2017 19
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 20
Gilead Sciences Acquires Farnesoid X Receptor Program from Phenex Pharma 28
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 30
Cell Design Labs Raises USD34.4 Million in Venture Financing 31
Kite Pharma Raises US$20 Million In Series A Financing 32
Kite Pharma Raises US$0.2 Million In Venture Financing 33
Kite Pharma Raises US$15 Million In Initial Round Of Financing 34
Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 35
Janssen Amends Licensing Agreement with Gilead for STR 36
Spring Bank Pharma Enters into Agreement with Gilead Sciences 37
Kite Pharma Forms Joint Venture with Fosun Pharma 38
Kite Pharma Enters into Agreement with Vitruvian Networks 39
Kite Pharma Enters into R&D Agreement with National Cancer Institute 40
Kite Pharma Enters into Agreement with Genentech 41
Gilead Sciences Enters into Co-Development Agreement with Galapagos 42
Kite Pharma Enters into Research Agreement with Leiden University Medical Center 43
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 44
Kite Pharma Enters into Research Agreement with GE Global Research 45
Spring Bank Pharma Enters into Agreement with Gilead Sciences 46
X-Rx Enters into Agreement with Gilead Sciences 47
Gilead Sciences Partners with WuXi PharmaTech 48
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 49
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 50
Adimab Enters into Research Agreement with Kite Pharma 51
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 52
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 53
Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 54
Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 55
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 56
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 58
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 59
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 60
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 62
Adimab Enters Into Co-Development Agreement With Gilead Sciences 63
CanAm Bioresearch Enters Into An Agreement With EpiTherapeutics 64
Zhejiang Conba Plans To Form Joint Venture With Kite Pharma 65
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine 66
Gilead Sciences Enters into Licensing Agreement with Medicines Patent Pool 67
Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 68
Genmab Enters into Licensing Agreement with Gilead Sciences 69
Kite Pharma Enters into Licensing Agreement with Cell Design Labs 70
Kite Pharma Exercises Option for Licensing Agreement with Adimab 71
Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 72
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 73
Amgen Enters into Licensing Agreement with Kite Pharma 75
Janssen Expands Licensing Agreement with Gilead 77
Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 78
Gilead Sciences Expands Licensing Agreement with Mylan Labs 79
Gilead Sciences Expands Licensing Agreement with Strides Shasun 80
Gilead Sciences Expands Licensing Agreement with Sun Pharma 82
Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 83
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 84
Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 85
Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 86
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 87
Medicines Patent Pool Enters into Licensing Agreement with Gilead Sciences 88
Fosun Pharma Kite Biotechnology Receives an Option to Product Candidates from Kite Pharma 89
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 90
Gilead Sciences Enters into Licensing Agreement with Polyphor 91
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 92
Kite Pharma Enters into Licensing Agreement with Regents of the University of California 93
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 94
Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 95
Natco Pharma Enters into Licensing Agreement with Gilead Sciences 96
Gilead Sciences Expands Licensing Agreement with Mylan Labs 97
Biocon Enters into Licensing Agreement with Gilead Sciences 98
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 99
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 100
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 102
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 103
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 104
Gilead Sciences Enters into Licensing Agreement with Hetero Labs 105
Gilead Sciences Enters into Licensing Agreement with Cipla 106
Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 107
Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 108
Gilead Sciences Plans To License Hepatitis C Drug, Sovaldi 109
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 110
Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 111
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 112
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 114
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 115
Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 116
Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 117
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat 118
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 119
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 120
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune 121
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 122
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 123
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 125
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad 126
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad 127
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 128
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 129
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread 130
VetDC Enters Into Licensing Agreement With Gilead Sciences For GS 9219 131
Kite Pharma Raises USD409.7 Million in Public Offering of Shares 132
Galapagos Raises USD425 Million in Private Placement of Shares 134
Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 135
Kite Pharma Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 137
Kite Pharma Announces Full Exercise of Underwriters Option in IPO to Raise up to USD147 Million 139
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 141
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 143
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 145
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 147
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 149
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 151
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 153
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 155
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 157
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 159
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 161
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 163
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 165
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 167
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 169
Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 171
Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 173
Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 175
Gilead Sciences Completes Public Offering Of Notes Due 2044 For US$1.75 Billion 177
Gilead Sciences Completes Public Offering Of Notes Due 2024 For US$1.75 Billion 179
Gilead Sciences Completes Public Offering Of Notes Due 2019 For US$500 Million 181
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1.25 Billion 183
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$1 Billion 184
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$700 Million 185
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 186
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1,000 Million 187
Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences 188
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 189
Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 190
United Therapeutics May Sell Itself 192
Gilead Sciences May Acquire Incyte 193
Novartis May Acquire Intercept Pharma 194
Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 195
Gilead Sciences Acquires EpiTherapeutics for USD65 Million 196
Kite Pharma Acquires T-Cell Factory 197
Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 198
Gilead Sciences Completes Acquisition Of Pharmasset For US$11.2 Billion 200
Gilead Sciences Acquires Calistoga Pharma 202
Gilead Sciences Acquires Arresto Biosciences 204
Gilead Sciences Inc, Key Competitors 206
Gilead Sciences Inc, Key Employees 207
Gilead Sciences Inc, Other Locations 208
Gilead Sciences Inc, Subsidiaries 208
Gilead Sciences Inc, Joint Venture 212
